As North American cannabis companies expand into Europe, Kojo Koram examines the risks of importing a profit-driven cannabis model before putting public health and social justice first.
Trimbos Institute hosts a webinar exploring how shifting geopolitical priorities in Europe are reshaping drug policy, public health and harm reduction services.
This joint civil society submission warns that restrictive laws and funding barriers are undermining the rights and operations of organisations supporting people who use drugs and other marginalised communities.
C-EHRN highlights shifting drug trends across Europe, noting the rising prevalence of polydrug use, potent synthetic substances, and the critical need for adapted harm reduction services.
Türkiye has re-nominated Prof. Sevil Atasoy for re-election to the International Narcotics Control Board, highlighting her extensive experience and commitment to human-centred, evidence-based global drug policies.
The European Commission’s proposed 2026–2030 EU Drugs Strategy shifts emphasis toward enforcement and border control, prompting calls to prioritise harm reduction, housing, community-based care and rights-based approaches.
EHRA provide a comparative assessment of harm reduction across Southeastern Europe, positioning political commitment and financing as critical to closing gaps.
We join 83 organisations urging EU Member States to revise the proposed Drug Strategy and reject a trafficking-only Action Plan, to ensure harm reduction, health and human rights remain central to EU drug policy.
The European Commission's new Drug Strategy promotes a worrying security-driven 'drug threat' narrative that fails to prioritise health and human rights over punishment.
